Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE -220.6%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $71M | $62M | $169M | $110M | $134M | $48M | — | — | — |
| Enterprise Value | $34M | $52M | $51M | $163M | $81M | $88M | $39M | — | — | — |
| P/E Ratio → | -0.91 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.55 | 4.22 | 6.61 | — | 3.87 | 3.01 | 6.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -220.6% | -220.6% | -3159.1% | -546.4% | -69.6% | -55.7% | -72.4% | — | — | — |
| ROA | -164.8% | -164.8% | -203.8% | -243.1% | -61.8% | -53.5% | -118.3% | -169.7% | -349.2% | -190.5% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
| ROCE | -216.0% | -216.0% | -334.2% | -263.0% | -70.1% | -55.9% | -199.8% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.16 | -1.13 | — | -1.00 | -1.03 | -1.07 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -802.48 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -12.27 | — | — | — | -0.14 | — | -10818.18 | -8119.05 |
Net cash position: cash ($20M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.80 | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | 0.09 | 0.73 |
| Quick Ratio | 5.80 | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 371.20 | 0.09 | 0.73 |
| Cash Ratio | 5.37 | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 | 13.96 | 0.00 | 0.06 | 0.71 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $21M | $12M | $9M | $8M | $8M | $6M | $7M | $4M | $4M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANVS stock.
Annovis Bio, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Annovis Bio, Inc.'s return on equity (ROE) is -220.6%. The historical average is -104.6%.
Based on historical data, Annovis Bio, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Binary clinical trial failure
Metrics are mathematically derived from official filings.
Speculative Valuation Amidst Clinical Uncertainty
As reported in financial statements, ANVS trades at a price-to-book ratio of 2.10, which reflects a significant discount compared to peers like ACADIA Pharmaceuticals, suggesting that the market is heavily discounting the company's intellectual property due to the binary nature of its upcoming clinical trial results.
The current P/B multiple appears to reflect a market that is pricing in the high probability of future equity dilution rather than the potential therapeutic value of Buntanetap. Investors should monitor whether this valuation gap narrows as the company approaches critical data readouts, as the current pricing suggests a lack of institutional confidence in the firm's standalone commercial path.
Capital Compounding Remains Fundamentally Negative
Based on the company's reported figures, the ROIC has deteriorated to -3.1% in 2025Q2, illustrating the inherent difficulty of generating positive returns on invested capital when the firm lacks commercial revenue and remains entirely dependent on external funding to sustain its research and development operations.
The negative ROIC trend is a structural reality for a pre-revenue biotech firm, as every dollar of invested capital is consumed by clinical trial expenses rather than productive assets. This trajectory warrants further investigation into whether management can achieve a pivot toward positive returns, or if the current model is destined for continued capital erosion until a strategic partnership is secured.
Liquidity Buffer Facing Rapid Compression
According to recent SEC filings, the current ratio has plummeted from 10.68 in 2025Q1 to 1.27 in 2026Q1, indicating that the company's liquidity position is narrowing rapidly as it funds the high-cost requirements of its ongoing Phase 3 clinical trials without any offsetting commercial revenue streams.
The rapid decline in the current ratio suggests that the company is approaching a critical liquidity inflection point that may necessitate immediate capital market intervention. Investors should monitor the cash burn rate closely, as the current buffer appears insufficient to support the company's long-term clinical roadmap without significant external financing.
Misapplication of Traditional Valuation Multiples
As indicated by the company's financial statements, the use of P/E ratios to evaluate ANVS is fundamentally flawed, as the firm generates no revenue and reports persistent net losses, rendering traditional earnings-based valuation metrics entirely irrelevant for assessing the company's true economic potential or its clinical progress.
Analysts should instead focus on the cash-burn-to-milestone ratio, which provides a more accurate assessment of how efficiently the company is converting its limited cash reserves into actionable clinical data. Relying on P/E or EV/EBITDA multiples in this context obscures the reality that the company's value is derived from binary clinical outcomes rather than current operational profitability.